Research progress on the role of myocardial cell calcium homeostasis dysregulation in heart failure

doi:10.16352/j.issn.1001-6325.2022.03.008

Abstract

Abstract: Calcium homeostasis of cardiomyocytes depends on the regulation of calcium(Ca²⁺) transportation through plasma membrane, sarco/endoplasmic reticulum(SR) and mitochondria. One of the main characteristics of heart failure is calcium homeostasis, including cytosolic calcium overload and SR calcium leakage, which leads to transient decrease of myocardial calcium and decrease of contractility.

Key words: calcium homeostasis, heart failure, calcium ATPase 2a, ryanodine receptor 2(RyR2)

CLC Number:

R541

LIU Feng-yu, HAN Wei. Research progress on the role of myocardial cell calcium homeostasis dysregulation in heart failure[J]. Basic & Clinical Medicine, 2022, 42(3): 502-506.

References

[1]中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018,46:760-789.
[2]Fink BD, Bai F, Yu L, et al. Regulation of ATP production: dependence on calcium concentration and respiratory state[J]. Am J Physiol Cell Physiol, 2017,313:C146-C153.
[3]Landstrom AP, Dobrev D, Wehrens X. Calcium signaling and cardiac arrhythmias[J]. Circ Res, 2017,120:1969-1993.
[4]Sanchez-Alonso JL, Loucks A, Schobesberger S, et al. Nanoscale regulation of L-type calcium channels differentiates between ischemic and dilated cardiomyopathies[J]. E Bio Med, 2020,57:102845.doi:10.1016/j.ebiom.2020.102845.
[5]Gross P, Johnson J, Romero CM, et al. Interaction of the joining region in junctophilin-2 with the L-type Ca²⁺ channel is pivotal for cardiac dyad assembly and intracellular Ca²⁺ dynamics[J]. Circ Res, 2020.doi:10.1161/CIRCRESAHA.119.315715
[6]Wang X, Zhuo X, Gao J, et al. Neuregulin-1β partially improves cardiac function in volume-overload heart failure through regulation of abnormal calcium handling[J]. Front Pharmacol, 2019,10:616.doi:10.3389/fphar.2019.00616.
[7]Primessnig U, Bracic T, Levijoki J, et al. Long-term effects of Na⁺/Ca²⁺ exchanger inhibition with ORM-11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction[J]. Eur J Heart Fail, 2019,21:1543-1552.
[8]Eder P. Cardiac remodeling and disease: SOCE and TRPC signaling in cardiac pathology[J]. Adv Exp Med Biol, 2017,993:505-521.
[9]Bartoli F, Bailey MA, Rode B, et al. Orai1 channel inhibition preserves left ventricular systolic function and normal Ca²⁺ handling after pressure overload[J]. Circulation, 2020,141:199-216.
[10]Kho C, Lee A, Jeong D, et al. Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure[J]. Nat Commun, 2015,6:7229.
[11]Kolstad TR, van den Brink J, MacQuaide N, et al. Ryanodine receptor dispersion disrupts Ca²⁺ release in failing cardiac myocytes[J]. eLife, 2018,7.doi:10.7554/eLife.39427
[12]Zhang Y, Wang WE, Zhang X, et al. Cardiomyocyte PKA ablation enhances basal contractility while eliminates cardiac β-adrenergic response without adverse effects on the heart[J]. Circ Res, 2019,124:1760-1777.
[13]Pollak AJ, Liu C, Gudlur A, et al. A secretory pathway kinase regulates sarcoplasmic reticulum Ca²⁺ homeostasis and protects against heart failure[J]. eLife, 2018,7.doi:10.7554/eLife.41378
[14]Pollak AJ, Haghighi K, Kunduri S, et al. Phosphoryla-tion of serine96 of histidine-rich calcium-binding protein by the Fam20C kinase functions to prevent cardiac arrhythmia[J]. Proc Nati Acad Sci U S A, 2017,114:9098-9103.
[15]Kwong JQ. The mitochondrial calcium uniporter in the heart: energetics and beyond[J]. J Physiol, 2017,595:3743-3751.
[16]Zaglia T, Ceriotti P, Campo A, et al. Content of mitochondrial calcium uniporter (MCU) in cardiomyocytes is regulated by microRNA-1 in physiologic and pathologic hypertrophy[J]. Proc Natl Acad Sci USA, 2017,114:E9006-E9015.
[17]Yu Z, Chen R, Li M, et al. Mitochondrial calcium uniporter inhibition provides cardioprotection in pressure overload-induced heart failure through autophagy enhancement[J].Inter J Cardiol, 2018,271:161-168.
[18]吴锦波, 叶小汉, 冼绍祥, 等. 比索洛尔提高心力衰竭大鼠心肌SERCA2a活性[J]. 基础医学与临床,2017, 37: 386-390.
[19]Hulot JS, Salem JE, Redheuil A, et al. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial[J]. Eur J Heart Fail, 2017,19:1534-1541.
[20]Lyon AR, Babalis D, Morley-Smith AC, et al. Investiga-tion of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device-the SERCA-LVAD TRIAL[J]. Gene Ther, 2020,27:579-590.
[21]Gorski PA, Jang SP, Jeong D, et al. Role of SIRT1 in modulating acetylation of the sarco-endoplasmic reticulum Ca²⁺-ATPase in heart failure[J]. Circulation Res, 2019,124:e63-e80.
[22]Keceli G, Majumdar A, Thorpe CN, et al. Nitroxyl (HNO) targets phospholamban cysteines 41 and 46 to enhance cardiac function[J]. J Gen Physiol, 2019,151:758-770.
[23]Felker GM, Borentain M, Cleland JG, et al. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure[J]. Eur J Heart Fail, 2019,21:1022-1031.
[24]Kobayashi S, Wakeyama T, Ono S, et al. A multicenter, randomized, double-blind, controlled study to evaluate the efficacy and safety of dantrolene on ventricular arrhythmia as well as mortality and morbidity in patients with chronic heart failure (SHO-IN trial): rationale and design[J]. J Cardiol, 2020,75:454-461.
[25]Ashna A, van Helden DF, Dos Remedios C, et al. Phenytoin reduces activity of cardiac ryanodine receptor 2; a potential mechanism for its cardioprotective action[J]. Mol Pharmacol, 2020,97:250-258.